Flow-diverter stents for endovascular management of non-fetal posterior communicating artery aneurysms-analysis on aneurysm occlusion, vessel patency, and patient outcome
UMass Chan Affiliations
New England Center for Stroke ResearchDivision of Neuroimaging and Intervention, Department of Radiology
Document Type
Journal ArticlePublication Date
2018-02-22Keywords
Intracranial aneurysmflow diverter
posterior communicating artery
stent
Cardiovascular Diseases
Equipment and Supplies
Nervous System Diseases
Radiology
Surgery
Metadata
Show full item recordAbstract
Background Use of flow-diversion technology in the treatment of incidental and recanalized posterior communicating artery (PComA) aneurysms. Methods Patients treated with the Pipeline embolization device (PED) for PComA aneurysms were identified and included in our retrospective analysis. We evaluated aneurysm characteristics, modified Rankin Scale score (mRS) on admission, angiography follow-up, and patient clinical outcome at discharge, at three to nine months, and at 12-18 months. Results We included 56 patients with a mean age of 56 years. Median mRS on admission was 0. All aneurysms involved the PComA and were either new findings or found to have shown recanalization at angiography follow-up from previous coil embolization or surgical clipping. Intraprocedural device foreshortening was observed in one case requiring additional placement of a self-expanding stent. One intraprocedural aneurysm rupture occurred because of a broken distal wire. This patient had an mRS of 4 after the procedure. Three- to nine-month and 12- to 18-month follow-up angiography showed near complete or complete aneurysm occlusion in most cases. Minimal to mild intimal hyperplasia was seen in five cases at three to nine months. PComA patency over time showed 29 of 46 initially patent vessels still patent at six months. Thirteen and seven PComAs showed progressive decrease in flow at three to nine months and 12-18 months, respectively. Median mRS remained 0 for all patients at three- to nine-month and 12- to 18-month follow-up. Conclusions Our preliminary results show that flow-diversion technology is an effective and safe treatment option. Larger studies with long-term follow-up are needed to validate our promising results.Source
Interv Neuroradiol. 2018 Jan 1:1591019918759735. doi: 10.1177/1591019918759735. [Epub ahead of print] Link to article on publisher's site
DOI
10.1177/1591019918759735Permanent Link to this Item
http://hdl.handle.net/20.500.14038/48274PubMed ID
29471704Related Resources
ae974a485f413a2113503eed53cd6c53
10.1177/1591019918759735